Valeant agrees to buy Coria Labs
From Times Wire Services
Valeant Pharmaceuticals International agreed to buy Coria Laboratories for $95 million, adding the closely held drug maker’s U.S. skin drugs.
Valeant will buy all outstanding shares of the Fort Worth company from Coria parent DFB Pharmaceuticals Inc. and other shareholders, Valeant said. The deal will add to Valeant’s earnings next year, the Aliso Viejo drug maker said.
Valeant’s products include Efudex for sun-damaged skin and Virazole for infant respiratory infections.
